My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

67.65 +0.57 (+0.85%)

Streaming Delayed Price Updated: 11:39 AM EDT, Apr 10, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Halozyme Therapeutics, Inc. - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

While growth is established for NASDAQ:HALO, the stock's valuation remains reasonable. ↗

September 26, 2023

HALOZYME THERAPEUTICS INC (NASDAQ:HALO) is showing decent growth, but is still valued reasonably.

Via Chartmill

7 Sleeper Stocks That Should Be on Every Investor’s Radar This Fall ↗

September 23, 2023

Discover the thrill of undervalued and overlooked sleeper stocks poised for growth in a shifting market environment.

Via InvestorPlace

Where Halozyme Therapeutics Stands With Analysts ↗

September 08, 2023

Via Benzinga

Expert Ratings for Halozyme Therapeutics ↗

August 15, 2023

Via Benzinga

Johnson & Johnson, Other Pharma Makers Anticipate Reformulated Injectable Drugs May Exclude Price Negotiations ↗

July 28, 2023

Cancer drug manufacturers, including Johnson & Johnson (NYSE: JNJ), anticipate that injectable versions of some popular treatments will not be included in U.S.

Via Benzinga

Halozyme's Subcutaneous Drug Delivery: Analysts Initiate With 'Buy' Rating, Say Enhanze Tech Targets $41.7B Market ↗

July 24, 2023

HC Wainwright has initiated coverage on Halozyme Therapeutics Inc (NASDAQ: HALO) with a Buy rating and a

Via Benzinga

Halozyme Therapeutics: Q1 Earnings Insights ↗

May 09, 2023

Via Benzinga

Halozyme Therapeutics Earnings Preview ↗

May 08, 2023

Via Benzinga

The Latest Analyst Ratings for Halozyme Therapeutics ↗

March 16, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023 ↗

July 24, 2023

Via Benzinga

Roche's Approved Multiple Sclerosis Drug: Subcutaneous Injection At Par With Intravenous Infusion ↗

July 13, 2023

Roche Holdings AG's (OTC: RHHBY) Phase 3 OCARINA II trial evaluating Ocrevus (ocrelizumab) as a twice-a-year 10-minute subcutaneous injection met its primary and secondary endpoints in patients with...

Via Benzinga

5 Analysts Have This to Say About Halozyme Therapeutics ↗

February 22, 2023

Via Benzinga

Halozyme Therapeutics's Earnings: A Preview ↗

February 20, 2023

Via Benzinga

Where Halozyme Therapeutics Stands With Analysts ↗

December 08, 2022

Via Benzinga

5 Analysts Have This to Say About Halozyme Therapeutics ↗

December 08, 2022

Via Benzinga

Argenx's Vyvgart Hytrulo Becomes First FDA Approved Subcutaneous Option For Generalized Myasthenia Gravis ↗

June 21, 2023

The FDA has approved Argenx SE's (NASDAQ: ARGX) Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), an injection for subcutaneous (SC) use for generalized myasthenia gravis (gMG) in adult...

Via Benzinga

10 Health Care Stocks With Whale Alerts In Today's Session ↗

June 20, 2023

Via Benzinga

AI Frenzy Helps Nasdaq 100 Outshine Russell 2,000 And Soar To Dot-Com Bubble Highs ↗

May 31, 2023

The surge of artificial intelligence (AI) is sparking a transformative shift in the relative valuations of prominent U.S. stock averages as the tech sector outperforms other industries and small-cap...

Via Benzinga

7 Meme Stocks to Buy Before They Soar to New Heights in 2023 ↗

May 25, 2023

Investing in meme stocks is no longer about driving dying companies higher. In fact, let’s get into meme-worthy and investment-grade shares.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For May 10, 2023 ↗

May 10, 2023

Via Benzinga

Medicare Negotiation Hammers Biotech Stocks Regeneron, Halozyme ↗

March 16, 2023

It's still unclear whether CMS will include those drugs in its negotiation list.

Via Investor's Business Daily

Benzinga's Top Ratings Upgrades, Downgrades For March 16, 2023 ↗

March 16, 2023

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

May 08, 2023

On Monday, 61 companies hit new 52-week lows.

Via Benzinga

Stock Market Rally Gains Steam As Inflation Cools; Tesla Price Cuts, Big Earnings In Focus: Weekly Review ↗

January 13, 2023

Sharp Tesla price cuts and some notable earnings were in focus.

Via Investor's Business Daily

Nasdaq Rises Over 1%; CommVault Systems Shares Plummet ↗

January 11, 2023

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining more than 100 points on Wednesday.

Via Benzinga

Why Broadwind Shares Are Trading Higher By 85%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

January 11, 2023

Gainers Broadwind Inc (NASDAQ: BWEN) shares climbed 85.4% to $4.19 after the company announced the receipt of approximately $175 million in new tower orders from a leading global wind turbine...

Via Benzinga

CommVault Systems, Halozyme Therapeutics And Other Big Stocks Moving Lower On Wednesday ↗

January 11, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 80 points on Wednesday. Here are some big stocks recording losses in today’s session.

Via Benzinga

US Stocks Open Higher; Nasdaq Rises 60 Points ↗

January 11, 2023

U.S. stocks traded higher this morning, with the Nasdaq gaining around than 600 points on Wednesday.

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

November 28, 2022

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity...

Via Benzinga

Stocks That Hit 52-Week Lows On Thursday ↗

December 01, 2022

During Thursday's session, 108 stocks hit new 52-week highs.

Via Benzinga

< Previous 1 2

...

6 7 8 9 10 11 12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.